India Globalization Capital, Inc. announced it has received a no objection letter from Health Canada for approval of its trial, A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease. The no objection letter provides the acknowledgement of IGC-AD1's drug candidacy and the authority to proceed with Phase 2 trials in Canada. IGC-AD1 relies on low doses of THC, a psychoactive cannabinoid, and another compound as active agents in trials for Alzheimer's. The formulation recently commenced Phase 2 of clinical trials required by the FDA and demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating a key protein that is responsible for Aß plaques a key hallmark of the disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4491 USD | +0.25% | +4.20% | +60.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.34% | 33.89M | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- IGC Stock
- News IGC Pharma, Inc.
- India Globalization Capital, Inc. Receives No Objection Letter from Health Canada